# US 11,299,768 B2 · Methods for determining a patient's susceptibility of contracting a nosocomial infection and for establishing a prognosis of the progression of septic syndrome

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 11,299,768 B2
- Document ID: US11299768B2
- Status: Granted
- Kind: B2
- Application number: 13/140,678
- Filed: 2010-01-18
- Published: 2011-10-13
- Granted: 2022-04-12
- Earliest claimed: 2009-01-19
- Assignees: Biomerieux; Hospices Civils De Lyon
- Applicants: Marie-Angelique Cazalis; Alain Lepape; Guillaume Monneret; Bruno Mougin; Alexandre Pachot
- Inventors: Marie-Angelique Cazalis; Alain Lepape; Guillaume Monneret; Bruno Mougin; Alexandre Pachot
- Web page: https://patentgrep.com/patent/US11299768B2

## CPC

- C12Q 1/6809: Methods for determination or identification of nucleic acids involving differential detection
- C12Q 1/6813: Hybridisation assays
- C12Q 1/686: Polymerase chain reaction [PCR]
- C12Q 1/6865: Promoter-based amplification, e.g. nucleic acid sequence amplification [NASBA], self-sustained sequence replication [3SR] or transcription-based amplification system [TAS]
- C12Q 1/6876: Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q 1/6883: for diseases caused by alterations of genetic material
- C12Q 1/6886: for cancer (immunoassay for cancer G01N33/575)
- C12Q 2521/107: RNA dependent DNA polymerase,(i.e. reverse transcriptase)
- C12Q 2545/10: the purpose being quantitative analysis
- C12Q 2561/113: Real time assay
- C12Q 2600/118: Prognosis of disease development
- C12Q 2600/158: Expression markers
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES

## Abstract

A method for determining a patient's susceptibility of contracting a nosocomial infection that includes obtaining a biological sample from the patient and extracting biological material from the biological sample; preparing a specific reagent of an expression product of at least one target gene selected from S100A9 and S100A8 target genes; and determining the expression of at least one of the target genes S100A9 and S100A8, where overexpression relative to a specified threshold value indicates susceptibility of contracting a nosocomial infection.

## Claims

### Claim 1

A method comprising:
a) obtaining blood samples from a human patient with septic shock at multiple time points after septic shock onset, at least one of the time points being between 7 and 10 days after septic shock onset;
b) extracting nucleic acids from the blood samples; and
c) measuring an overexpression of the S100A9 gene relative to a predetermined threshold value in at least the blood sample(s) obtained between 7 and 10 days after septic shock onset,
wherein the overexpression is measured via an amplification method comprising the use of a first primer consisting of SEQ ID NO: 1 and a second primer consisting of SEQ ID NO: 2.

### Claim 2 (depends on 1)

The method as claimed in claim 1, wherein RNA is the nucleic acid extracted from the blood samples, and cDNA is generated from the RNA by an amplification method.

### Claim 3 (depends on 1)

The method as claimed in claim 1, wherein the amplification method is a real-time PCR amplification method.

### Claim 4 (depends on 1)

The method according to claim 1, wherein septic shock is characterized by an identified infectious site and persistent hypotension.

### Claim 5

A method comprising:
a) obtaining blood samples from a human patient with septic shock at multiple time points after septic shock onset, at least one of the time points being between 7 and 10 days after septic shock onset;
b) extracting nucleic acids from the blood samples; and
c) measuring an overexpression of the S100A8 gene relative to a predetermined threshold value in at least the blood sample(s) obtained between 7 and 10 days after septic shock onset, the threshold value being indicative of either a healthy subject or a non-surviving septic shock patient,
wherein the overexpression is measured via an amplification method comprising the use of a first primer consisting of SEQ ID NO: 3 and a second primer consisting of SEQ ID NO: 4.

### Claim 6 (depends on 5)

The method as claimed in claim 5, wherein RNA is the nucleic acid extracted from the blood samples, and cDNA is generated from the RNA by an amplification method.

### Claim 7 (depends on 5)

The method as claimed in claim 5, wherein the amplification method is a real-time PCR amplification method.

### Claim 8 (depends on 5)

The method according to claim 5, wherein septic shock is characterized by an identified infectious site and persistent hypotension.